Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community.

32 In the on-statin arm, however, ApoB failed to reach significance (HR: 1.20, 95% CI 0.98 to 1.46 for incident CVD). 32 Strengths and limitations The strengths of our investigation include the large community-based sample, the careful and comprehensive characterisation of our study participants, including measures of subclinical atherosclerosis at the carotid arteries and of biomarkers of systemic inflammation and neurohormonal activation, and the prospective follow-up for incident CVD (median follow-up, 13.7 years).

also in 4,113 other papers